Rwanda Impact, Mid-Year 2012

Mid-year 2012, PSI has averted an estimated 87,534 DALYs in Rwanda. This is 54% of their own program target for 2012.

RWANDA PROGRAM PERFORMANCE

	2012 YTD	% Change from 2011 YTD	% 2012 Program Target	2012 Program Target
SCALE				
DALYs Averted	87,534	188%	54%	162,921
Couple Years of Protection (CYP)*	61,530	150%	45%	137,803
Burden Averted	1.1%			

RELEVANCE		VALUE		
Health Relevance	45%	2011 Net Cost per DALY	\$101	
■ Family Planning Method Mix**	5 with 1 LTM	2011 Net Cost per CYP	\$65	

^{*} CYPs based on new USAID conversion factors, except IUDs




RWANDA HEALTH AREA PERFORMANCE						
Current PSI Product & Service Health Areas		% of Country				
	DALYs Averted	% Change from 2011 YTD	Burden Averted	Total Burden		
HIV & STD	26,957	162%	4.4%	11.2%		
Reproductive Health	13,067	147%	1.4%	17.1%		
Malaria	46,274	238%	7.1%	5.1%		
Diarrheal Diseases	1,236	16%	0.2%	11.7%		
Potential 24% increase in releva	% of Country Total Burden					
Tuberculosis				3.5%		
Nutritional Deficiencies				4.3%		
Respiratory Infections				15.9%		

RWANDA				
Platform Profile				
Population	10,624,005			
Population under 5	1,830,654			
Women aged 15-49	2,622,084			
# Platform interventions	10			
# Family planning interventions	5 with 1 LTM			
Contraceptive prevalence	26.1% (2008)			

^{*} Population data from UN Population Division, 2010 revision

PSI RELEVANCE: 2012 DALYS AVERTED YTD COMPARED TO BURDEN OF DISEASE (WHO 2004)*



- Innovation in Other Health Areas: Burden from non-communicable diseases and injuries
- Innovation in Communicable Diseases: Additional communicable burden not addressed by PSI
- Expansion: % disease burden targeted by existing PSI products and services not in use by country platform
- **Health Relevance**: % disease burden targeted by current country platform products and services
- Burden Averted: % DALYs averted by PSI in 2012 YTD as proportion of WHO (2004) Burden of Disease DALYs
 - In 2012 YTD, 0.5% of global DALYs were averted by PSI.
 - In Rwanda, 1.1% of DALYs were averted by PSI in 2012 YTD.


Note: Updated WHO Global Burden of Disease estimates produced by IHME are anticipated late 2012

PSI IMPACT 2012 MID-YEAR 1

^{**} Target is 4 or more FP modern methods with at least one long-term method

RWANDA PRODUCTS & SERVICES DALYS AVERTED (from highest to lowest DALYs averted) 2012 YTD % Change from 2012 YTD 2012 Targeted % of 2012 **Products** 2011 unit COGS 2012 YTD CYPs 2011 YTD Distribution **DALYs** # Distributed **Target** LLINs 40,606 2195738% 175,667 200,000 88% \$4.24 37,599 6,232,673 14,000,000 \$0.04 Condom 166% 45% 51,939 Malaria PPT (ACT) 5,667 -59% 155,740 470,000 33% \$0.42 Safe Water Solution 1,170 12% 64,011 550,000 12% \$0.19 **OCs** 894 86% 63,517 55,000 115% \$0.36 4,234 VCT 570 51% 22,840 38,500 59% \$0.95 Injectable 3 22% 9,855 20,000 49% \$0.73 2.464 505 1,900 Implant 5 Distribution 298 580 31% \$21.20 2,204 SDM (Cycle Beads) 158 -11% 459 2,500 18% \$0.93 689 **PUR** 274% 358,410 1,500,000 24% \$0.04 66 **IUD** Insertion 0 400 0% * **Emergency Contraception** 0 2,000 0% Total 87,534 188% 61,530

^{**} DALYs averted and CYPs provided may be negative for products distributed in cases where PSI has distributed and inserted the same product. This is because DALYs averted and CYPs are calculated separately for products that are distributed and inserted; to avoid double counting, insertion DALYs and CYPs are subtracted from distribution.



PSI IMPACT 2012 MID-YEAR 2

^{*} Product was not distributed in YTD 2011